Anzeige
Mehr »
Login
Mittwoch, 29.01.2025 Börsentäglich über 12.000 News von 684 internationalen Medien
Absoluter Geheimtipp: Vergessen Sie Gold, Silber und Uran!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
455 Leser
Artikel bewerten:
(2)

Veeva Systems: LEO Pharma Connects Affiliates with Veeva Vault Safety to Transform Safety Operations

Finanznachrichten News

Medical dermatology leader eliminates data silos and gains real-time oversight

BARCELONA, Spain, Oct. 3, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that LEO Pharma, a global leader in medical dermatology, is using Veeva Vault Safety to optimize its safety operations. With this foundation, the company can seamlessly incorporate affiliates into safety workflows, boost operational efficiencies, ensure compliance, and unify its global pharmacovigilance data on one platform.

Veeva Systems

"LEO Pharma is deeply committed to the safety of patients using its products," said Pilar Carrero, vice president of global safety at LEO Pharma. "With Veeva Vault Safety, we now have real-time visibility into adverse events and data transparency for affiliates that helps us work even better together."

Vault Safety is helping LEO Pharma improve oversight of case intake, processing, submission, and distribution while simplifying safety workflows and eliminating data reconciliation with affiliates and partners. By standardizing drug development on Veeva Development Cloud, LEO Pharma can better connect safety to other crucial business areas like clinical, regulatory, and quality.

"Now, all parties have visibility into case data, ownership, and status, facilitating improved collaboration and sharing of learnings," said John Lawrie, vice president of Vault Safety at Veeva. "Veeva is happy to partner with LEO Pharma to make its safety operations simpler and more effective."

Vault Safety is a safety case management system that enables end-to-end adverse event intake, processing, and submission for clinical and marketed products. It is part of Veeva Development Cloud, the technology foundation for drug development that brings together clinical, regulatory, safety, and quality applications to drive end-to-end business processes.

Additional Information
For more on Veeva Vault Safety, visit: veeva.com/eu/VaultSafety
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Photo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/leo-pharma-connects-affiliates-with-veeva-vault-safety-to-transform-safety-operations-301945288.html

© 2023 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.